An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 5, 2008, Pages 967-976

  Colombo, Giorgio L ^a   Caruggi, Mauro ^b   Di Matteo, Sergio ^a   Rossi, Alessandro ^c  

^a SAVE Studi Analisi Valutazioni Economiche   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Apripiprazole; Cost consequences; Diabetes; Metabolic syndrome; Olanzapine; Schizophrenia

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; BIGUANIDE DERIVATIVE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; NICOTINIC ACID DERIVATIVE; OLANZAPINE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; ITALY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POPULATION RISK; PREDICTION; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

EID: 56849107257     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3701     Document Type: Article

References (59)

1. [ADA/APA/AACE/NAASO] American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care, 27:596-601.
2. [ADA] American Diabetes Association. 1998. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care, 21:296-309.
3. Allochis G, Cavallaro, R, Milano W, et al. 2008. Bisogni irrisolti nel trattamento della schizofrenia: ruolo di aripiprazolo. Giornale Italiano di Psicopatologia, 14:88-104.
4. Allison DB, Fontaine KR, Heo M, et al. 1999. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry, 60:215-20.
5. Brown GD. 1998. The biosynthesis of steroids and triterpenoids. Natural Product Reports, 15:653-96.
6. Burke JP, Williams K, Gaskill SP, et al. 1999. Rapid rise in the incidence oftype 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med, 159:1450-6.
7. Citrome L, Jaffe A, Levine J. 2007. Datapoints: The ups and downs of dosing second-generation antipsychotics. Psychiatr Serv, 58:11.
8. de Leon J, Dadvand M, Canuso C, et al. 1995. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry, 152:453-5.
9. Dixon L, Weiden P, Delahanty J, et al. 2000. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull, 26:903-12.
10. Enger C, Weatherby L, Reynolds RF, et al. 2004. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis, 192:19-27.
11. Faulkner G, Cohn T, Remington G, et al. 2006. Body mass index, waist circumferences and quality of life in individuals with schizophrenia. Schizophr Res, 90:174-8.
12. Folsom DP, Hawthorne W, Lindamer L, et al. 2005. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psychiatry, 162:370-6.
13. Ford ES. 2004. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis, 173:309-14.
14. Graham KA, Cho H, Brownley KA, et al. 2008. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episodi psychosis subjects. Schizophr Res, 101:297-94.
15. Graves EJ, Gillum BS. 1996. 1994 summary: National Hospital Discharge Survey. Adv Data, 278:1-12.
16. Guest JF, Cookson RF. 1999. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. PharmacoEconomics, 15:597-610.
17. Health Ministry. 2006a. National Tariff Nomenclature. Nomenclatore delle Prestazioni di assistenza specialistica ambulatoriale. Ministero della Salute.
18. Health Ministry. 2006b. Hospital DRG tariffs. Tariffa Unica Convenzionale, National DRG Tariff. Ministerial Decree DM 12/09/2006.
19. Health Ministry. 2007. OSMED, Osservatorio sui farmaci dell'Agenzia italiana del farmaco (AIFA - Italian Drug Agency).
20. Henderson DC, Cagliero E, Gray C, et al. 2000. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry, 157:975-81.
21. Hughes JR, Hatsukaim DK, Mitchell JE, et al. 1986. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry, 143:993-7.
22. Italian inflation rates. 2007. [online] Accessed July 2007. URL: http://www.istat.it/prezzi/precon/rivalutazioni
23. Jablensky A. 2000. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci, 250:274-85.
24. Kane JM, Carson WH, Saha AR et al. 2002. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry, 63:763-71.
25. Knapp M. 2000. Schizophrenia costs and treatment cost-effectiveness, Acta Psychiatrica Scandinavica, 102(Suppl 407):15-18(4).
26. Koro CE, Fedder DO, L'Italien GJ, et al. 2002. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ, 325:243-7.
27. Kurzthaler I, Fleischhacker WW. 2001. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry, 62:32-7.
28. Lakka HM, Laaksonen DE, Lakka TA et al. 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288:2709-16.
29. Lambert BL, Chou C-H, Chang K-Y, et al. 2005. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf, 14:417-25.
30. Lean ME, Han TS, Morrison CE. 1995. Waist circumference as a measure for indicating need for weight management. BMJ, 311:158-61.
31. Leslie DL, Rosenheck RA. 2004. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry, 161:1709-11.
32. L'informatore farmaceutico 2007. Medicinali, Masson-Elsevier.
33. L'Italien GJ, Casey DE, Kan HJ, et al. 2007. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry, 68:1510-6.
34. Lucioni C, Garancini MP, Massi-Benedetti M, et al. 2000. The social cost of type 2 diabetes in Italy: the CODE-2 study. PharmacoEconomics - Italian Research Articles, 2:1-21.
35. Lucioni C, Mazzi S, Serra G. 2001. Drug costs and and treatment patterns in patients with type-2 diabetes mellitus: results from CODE-2 study. PharmacoEconomics - Italian Research Articles, 3:1-14.
36. Marder SR, McQuade RD, Stock E, et al. 2003. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res, 61:123-36.
37. McCue RE, Waheed R, Urcuyo L, et al. 2006. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry, 189:43 3-40.
38. McEvoy JP, Meyer JM, Goff DC, et al. 2005. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res, 80: 19-32.
39. McQuade RD, Stock E, Marcus R, et al. 2004. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry, 65:47-56.
40. Nasrallah HA. 2002. Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy. Am J Health Syst Pharm, 59(Suppl 8):S16-S21.
41. Nemeroff CB. 1997. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry, 58:45-9.
42. [NCEP] National Cholesterol Education Program. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285:2486-97.
43. Newcomer JW. 2005. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19:1-93.
44. Ray S, Corey-Lisle PK, Cislo PR, et al. 2004. An economic evaluation of aripiprazole compared to olanzapine based on metabolic side-effect profile. Eur Neuropsychopharmacol, 14(Suppl 3):S279.
45. Ridker PM, Buring JE, Cook NR, et al. 2003. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation, 107:391-7.
46. Ryan MC, Thakore JH. 2002. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci, 71:239-57.
47. Ryan MC, Collins P, Thakore JH. 2003. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry, 160:294-9.
48. Ryan PM. 1991. Epidemiology, etiology, diagnosis, and treatment of schizophrenia. Am J Hosp Pharm, 48:1271-80.
49. Sattar N, Gaw A, Scherbakova O, et al. 2003. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108:414-9.
50. Scarcella C, Indelicato A, Levaggi R, et al. 2006. The cost of diabetes: the Brescia's experience. PharmacoEconomics - Italian Research Articles, 8:95-103.
51. Schappert SM. 1996. National Ambulatory Medical Care Survey: 1994 summary. Adv Data, 273:1-18.
52. Sernyak MJ, Leslie DL, Alarcon RD, et al. 2002. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry, 159:561-6.
53. Stern MP, Williams K, Haffner SM. 2002. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med, 136:575-81.
54. Strahan GW. 1996. An overview of home health and hospice care patients: 1994 National Home and Hospice Care Survey. Adv Data, 274:1-8.
55. Strahan GW. 1997. An overview of nursing homes and their current residents: data from the 1995 National Nursing Home Survey. Adv Data, 280:1-12.
56. Susce MT, Villanueva N, Diaz FJ, et al. 2005. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry, 66:167-73.
57. Thompson JL, Pogue-Geile MF, Grace AA. 2004. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophr Bull, 30:875-900.
58. Weiden PJ, Waldeck R, Tafesse E, et al. 2003. Aripiprazole is not associated with increased diabetes risk: a long-term model [poster]. American Psychiatric Association 156th Annual Meeting, San Francisco, CA.
59. Wirshing DA. 2004. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry, 65(Suppl 18):S13-26.